Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms.

PURPOSE To assess retrospectively the incremental value of endorectal coil magnetic resonance (MR) imaging and combined endorectal MR imaging-MR spectroscopic imaging to the staging nomograms for predicting organ-confined prostate cancer (OCPC). MATERIALS AND METHODS The institutional review board approved this HIPAA-compliant study and issued a waiver of informed consent for review of the MR reports and clinical data. Between November 1, 1999, and November 1, 2004, 229 patients underwent endorectal MR imaging and 383 underwent combined endorectal MR imaging-MR spectroscopic imaging before radical prostatectomy. Mean patient age was 58 years (range, 32-74 years). MR studies were interpreted prospectively by 12 radiologists who were informed of patients' clinical data. On the basis of the MR reports, the risks of extracapsular extension, seminal vesicle invasion, and lymph node metastasis were scored retrospectively from 1 to 5; the highest score was subtracted from 6 to determine a score (from 1 to 5) for the likelihood of OCPC on MR studies. The staging nomograms were used to calculate the likelihood of OCPC on the basis of serum prostate-specific antigen level, Gleason grade at biopsy, and clinical stage. Histopathologic findings constituted the reference standard. Logistic regression was used to estimate the multivariable relations between OCPC and MR findings. The area under the receiver operator characteristic curve was calculated for each model. The jackknife method was used for bias correction. RESULTS MR findings contributed significant incremental value (P </= .02) to the nomograms in the overall study population. The contribution of MR findings was significant in all risk groups but was greatest in the intermediate- and high-risk groups (P < .01 for both). Accuracy in the prediction of OCPC with MR was higher when MR spectroscopic imaging was used, but the difference was not significant. CONCLUSION Endorectal MR imaging and combined endorectal MR imaging-MR spectroscopic imaging contribute significant incremental value to the staging nomograms in predicting OCPC.

[1]  H. Hricak,et al.  Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. , 2006, Radiology.

[2]  Lawrence H Schwartz,et al.  Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. , 2006, AJR. American journal of roentgenology.

[3]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.

[4]  Vassilis Poulakis,et al.  Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage. , 2004, The Journal of urology.

[5]  P. Carroll,et al.  Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. , 2004, AJR. American journal of roentgenology.

[6]  Hedvig Hricak,et al.  Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[7]  Michael W Kattan,et al.  Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. , 2004, Radiology.

[8]  Michael W Kattan,et al.  Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. , 2004, Radiology.

[9]  Chinyere N. Onyebuchi,et al.  The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy , 2004, Cancer.

[10]  Chinyere N. Onyebuchi,et al.  Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. , 2003, Seminars in oncology.

[11]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[12]  A. Partin,et al.  Management of high-risk populations with locally advanced prostate cancer. , 2003, The oncologist.

[13]  D. Bostwick,et al.  Contemporary pathology of prostate cancer. , 2003, The Urologic clinics of North America.

[14]  N. Aaronson,et al.  Health related quality of life in men with prostate cancer. , 2003, The Journal of urology.

[15]  M. Kattan,et al.  Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. , 2002, The Journal of urology.

[16]  A. Renshaw,et al.  Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. , 2002, Urology.

[17]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[18]  L. Klotz,et al.  The role of serial free/total prostate‐specific antigen ratios in a watchful observation protocol for men with localized prostate cancer , 2002, BJU international.

[19]  Peter Carroll,et al.  Rising PSA after a Radical Treatment , 2001, European Urology.

[20]  J. Pow-Sang,et al.  Observation in the management of localized prostate cancer. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[21]  U Pichlmeier,et al.  A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. , 2001, The Journal of urology.

[22]  A W Partin,et al.  Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. , 2000, The Journal of urology.

[23]  J Kurhanewicz,et al.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 1999, Radiology.

[24]  W. Catalona,et al.  Contemporary results of anatomic radical prostatectomy , 1999, CA: a cancer journal for clinicians.

[25]  S. Friis,et al.  Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study. , 1999, The Journal of urology.

[26]  O. Ogawa,et al.  Preoperative Predictors for Organ‐Confined Disease in Japanese Patients with Stage T1c Prostate Cancer , 1998, International journal of urology : official journal of the Japanese Urological Association.

[27]  S B Malkowicz,et al.  Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. , 1998, Urology.

[28]  J. Kurhanewicz,et al.  Improved water and lipid suppression for 3D PRESS CSI using rf band selective inversion with gradient dephasing (basing) , 1997, Magnetic resonance in medicine.

[29]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[30]  A. D'Amico,et al.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. , 1995, The Journal of urology.

[31]  K. Gohji,et al.  USEFULNESS OF DIGITAL RECTAL EXAMINATION, SERUM PROSTATE‐SPECIFIC ANTIGEN, TRANSRECTAL ULTRAS ONOGRAPHY AND SYSTEMATIC PROSTATE BIOPSY FOR THE DETECTION OF ORGAN‐CONFINED PROSTATE CANCER , 1995, International journal of urology : official journal of the Japanese Urological Association.

[32]  C W Piccoli,et al.  Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. , 1994, Radiology.

[33]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[34]  H. Hricak,et al.  MR imaging of the seminal vesicles. , 1991, AJR. American journal of roentgenology.

[35]  W. Whitmore,et al.  Frozen section lymph node analysis in pelvic lymphadenectomy for prostate cancer. , 1988, The Journal of urology.

[36]  K. Uğurbil,et al.  NMR chemical shift imaging in three dimensions. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[38]  Pierre I Karakiewicz,et al.  Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. , 2004, The Journal of urology.

[39]  Pierre I Karakiewicz,et al.  Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. , 2003, European urology.

[40]  J Kurhanewicz,et al.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. , 2000, Neoplasia.

[41]  T. Wilt,et al.  Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee. , 1995, Journal of the National Cancer Institute. Monographs.

[42]  R. Peschel,et al.  Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment. , 1994, International journal of radiation oncology, biology, physics.